Apogee Therapeutics Management
Management criteria checks 0/4
Apogee Therapeutics' CEO is Michael Henderson, appointed in Sep 2022, has a tenure of 2.25 years. total yearly compensation is $8.67M, comprised of 6.5% salary and 93.5% bonuses, including company stock and options. directly owns 1.33% of the company’s shares, worth $35.73M. The average tenure of the management team and the board of directors is 1.9 years and 1.5 years respectively.
Key information
Michael Henderson
Chief executive officer
US$8.7m
Total compensation
| CEO salary percentage | 6.5% |
| CEO tenure | 2.3yrs |
| CEO ownership | 1.3% |
| Management average tenure | 1.9yrs |
| Board average tenure | 1.5yrs |
Recent management updates
Recent updates
We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate
Nov 14
Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis
Nov 10We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate
Jun 20Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play
Jun 18We're Interested To See How Apogee Therapeutics (NASDAQ:APGE) Uses Its Cash Hoard To Grow
Mar 05Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management
Mar 05We're Not Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn
Nov 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$147m |
| Jun 30 2024 | n/a | n/a | -US$118m |
| Mar 31 2024 | n/a | n/a | -US$104m |
| Dec 31 2023 | US$9m | US$565k | -US$84m |
| Sep 30 2023 | n/a | n/a | -US$70m |
| Jun 30 2023 | n/a | n/a | -US$69m |
| Mar 31 2023 | n/a | n/a | -US$52m |
| Dec 31 2022 | US$6m | US$146k | -US$43m |
Compensation vs Market: Michael's total compensation ($USD8.67M) is above average for companies of similar size in the US market ($USD6.65M).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
CEO
Michael Henderson (35 yo)
2.3yrs
Tenure
US$8,671,208
Compensation
Dr. Michael Thomas Henderson, M.D. serves as Chief Executive Officer at Apogee Therapeutics, Inc. since September 2022 and Director since June 2023. He had been Chief Business Officer of BridgeBio Pharma,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$8.67m | 1.33% $ 35.7m | |
| Chief Financial Officer | 1.9yrs | US$5.02m | 0.35% $ 9.5m | |
| Chief Medical Officer | 2.3yrs | US$4.17m | 0.19% $ 5.2m | |
| Vice President of Investor Relations | 1.4yrs | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 1.3yrs | no data | no data | |
| VP & Head of People | 2.1yrs | no data | no data | |
| Chief Development Officer | less than a year | no data | no data | |
| Senior Vice President of Clinical Operations | 1.9yrs | no data | no data | |
| Senior VP and Head of Regulatory Affairs & Toxicology | 2.2yrs | no data | no data | |
| Senior Vice President of Finance | 1.6yrs | no data | no data | |
| Senior Vice President of Program & Portfolio | no data | no data | no data | |
| Senior Vice President of Business Development & Strategy | no data | no data | no data |
1.9yrs
Average Tenure
48yo
Average Age
Experienced Management: APGE's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.5yrs | US$8.67m | 1.33% $ 35.7m | |
| Independent Director | 1.5yrs | US$414.57k | no data | |
| Independent Director | 1.5yrs | US$411.66k | no data | |
| Independent Director | 1.5yrs | US$664.82k | no data | |
| Independent Director | 1.5yrs | US$662.82k | 0.090% $ 2.4m | |
| Independent Chairman of the Board | 1.3yrs | US$972.87k | 0.035% $ 946.5k | |
| Independent Director | 1.5yrs | US$666.57k | no data | |
| Independent Director | 2.9yrs | US$668.57k | 0.090% $ 2.4m | |
| Director | less than a year | no data | no data |
1.5yrs
Average Tenure
41yo
Average Age
Experienced Board: APGE's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 04:36 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Apogee Therapeutics, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charlie Yang | BofA Global Research |
| Julian Harrison | BTIG |
| Edward Nash | Canaccord Genuity |